Home › Research › Drug development
Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies
Dina Rodrigues Martins, Fern Sha, Wim Van der Elst, Pei-Yu Shih, Jens Devoght, Kristof Van Kolen, Marc Mercken, Bianca Van Broeck et al.. Molecular therapy. Methods & clinical development, 2023-11-14
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
Over the last decade, there has been a growing interest in intrabodies and their therapeutic potential. Intrabodies are antibody fragments that are expressed inside a cell to target intracellular antigens. In the context of intracellular protein misfolding and aggregation, such as tau pathology in Alzheimer's disease, intrabodies have become an interesting approach as there is the possibility to target early stages of aggregation. As such, we engineered three anti-tau monoclonal antibodies into single-chain variable fragments for cytoplasmic expression and activity: PT51, PT77, and hTau21. Due to the reducing environment of the cytoplasm, single-chain variable fragment (scFv) aggregation is commonly observed. Therefore, we also performed complementarity-determining region (CDR) grafting into three different stable frameworks to rescue solubility and intracellular binding. All three scFvs retained binding to tau after cytoplasmic expression in HEK293 cells, in at least one of the frameworks. Subsequently, we show their capacity to interfere with either mouse or mutant human tau aggregation in two different primary mouse neuron models and organotypic hippocampal slice cultures. Collectively, our work extends the current knowledge on intracellular tau targeting with intrabodies, providing three scFv intrabodies that can be used as immunological tools to target tau inside cells.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Martins, D. R., Sha, F., Van der Elst, W., Shih, P.-Y., Devoght, J., Van Kolen, K., et al. (2023). Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies. Molecular therapy. Methods & clinical development. https://doi.org/10.1016/j.omtm.2023.101158
Vancouver
Martins DR, Sha F, Van der Elst W, Shih P.-Y, Devoght J, Van Kolen K, et al. Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies. Molecular therapy. Methods & clinical development. 2023. doi:10.1016/j.omtm.2023.101158. PMID: 38074413.
BibTeX
@article{martins2023-38074413,
author = {Martins, Dina Rodrigues and Sha, Fern and Van der Elst, Wim and Shih, Pei-Yu and Devoght, Jens and Van Kolen, Kristof and Mercken, Marc and Van Broeck, Bianca and others},
title = {{Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies}},
journal = {Molecular therapy. Methods \& clinical development},
year = {2023},
doi = {10.1016/j.omtm.2023.101158},
pmid = {38074413},
url = {https://doi.org/10.1016/j.omtm.2023.101158}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Due to the reducing environment of the cytoplasm, single-chain variable fragment (scFv) aggregation is commonly observed.
- Therefore, we also performed complementarity-determining region (CDR) grafting into three different stable frameworks to rescue solubility and intracellular binding.
- All three scFvs retained binding to tau after cytoplasmic expression in HEK293 cells, in at least one of the frameworks.
- Subsequently, we show their capacity to interfere with either mouse or mutant human tau aggregation in two different primary mouse neuron models and organotypic hippocampal slice cultures.
- Collectively, our work extends the current knowledge on intracellular tau targeting with intrabodies, providing three scFv intrabodies that can be used as immunological tools to target tau inside cells.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular therapy. Methods & clinical development) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38074413) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “phosphorylation”
389 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 389 tagged studies.